IDH2 and central nervous system cancer: To validate our finding of IGFBP2 as a specific prognostic marker of IDH-mutant glioma, we used an independent cohort of gliomas ranging from WHO grade II to grade IV with IDH status determined by immunohistochemistry against IDH1R132H [27].